1
|
Brassier A, Krug P, Lacaille F, Pontoizeau C, Krid S, Sissaoui S, Servais A, Arnoux JB, Legendre C, Charbit M, Scemla A, Francoz C, Benoist JF, Schiff M, Mochel F, Touati G, Broué P, Cano A, Tardieu M, Querciagrossa S, Grévent D, Boyer O, Dupic L, Oualha M, Girard M, Aigrain Y, Debray D, Capito C, Ottolenghi C, Salomon R, Chardot C, de Lonlay P. Long-term outcome of methylmalonic aciduria after kidney, liver, or combined liver-kidney transplantation: The French experience. J Inherit Metab Dis 2020; 43:234-243. [PMID: 31525265 DOI: 10.1002/jimd.12174] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 08/21/2019] [Accepted: 09/04/2019] [Indexed: 12/16/2022]
Abstract
Organ transplantation is discussed in methylmalonic aciduria (MMA) for renal failure, and poor quality of life and neurological outcome. We retrospectively evaluated 23 French MMA patients after kidney (KT), liver-kidney (LKT), and liver transplantation (LT). Two patients died, one after LKT, one of hepatoblastoma after KT. One graft was lost early after KT. Of 18 evaluable patients, 12 previously on dialysis, 8 underwent KT (mean 12.5 years), 8 LKT (mean 7 years), and 2 LT (7 and 2.5 years). At a median follow-up of 7.3 (KT), 2.3 (LKT), and 1.0 years (LT), no metabolic decompensation occurred except in 1 KT. Plasma and urine MMA levels dramatically decreased, more after LKT. Protein intake was increased more significantly after LKT than KT. Enteral nutrition was stopped in 7/8 LKT, 1/8 KT. Early complications were frequent after LKT. Neurological disorders occurred in four LKT, reversible in one. Five years after KT, four patients had renal failure. The metabolic outcomes were much better after LKT than KT. LKT in MMA is difficult but improves the quality of life. KT will be rarely indicated. We need more long-term data to indicate early LT, in the hope to delay renal failure and prevent neurodevelopmental complications.
Collapse
Affiliation(s)
- Anaïs Brassier
- Reference Center of Inherited Metabolic Diseases, Hôpital Universitaire Necker-Enfants Malades, APHP, Imagine Institute, Filière G2M, MetabERN, INEM, University Paris Descartes, Paris, France
| | - Pauline Krug
- Reference Center of Pediatric Nephrology, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière ORKID, ERKnet, University Paris Descartes, Paris, France
| | - Florence Lacaille
- Pediatric Hepatology Unit, Reference Center for rare pediatric liver diseases, Department of Gastroenterology-Hepatology-Nutrition, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière Filfoie, ERN Transplantchild, Paris, France
| | - Clément Pontoizeau
- Reference Center of Inherited Metabolic Diseases, Hôpital Universitaire Necker-Enfants Malades, APHP, Imagine Institute, Filière G2M, MetabERN, INEM, University Paris Descartes, Paris, France
- Metabolic Biochemistry, Hôpital Universitaire Necker-Enfants Malades, APHP, Imagine Institute, Filière G2M, MetabERN, University Paris Descartes, Paris, France
| | - Saoussen Krid
- Reference Center of Pediatric Nephrology, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière ORKID, ERKnet, University Paris Descartes, Paris, France
| | - Samira Sissaoui
- Pediatric Hepatology Unit, Reference Center for rare pediatric liver diseases, Department of Gastroenterology-Hepatology-Nutrition, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière Filfoie, ERN Transplantchild, Paris, France
| | - Aude Servais
- Reference Center of Inherited Metabolic Diseases, Hôpital Universitaire Necker-Enfants Malades, APHP, Imagine Institute, Filière G2M, MetabERN, INEM, University Paris Descartes, Paris, France
- Unit of Adult Nephrology and Transplantation, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière G2M, MetabERN, University Paris Descartes, Paris, France
| | - Jean-Baptiste Arnoux
- Reference Center of Inherited Metabolic Diseases, Hôpital Universitaire Necker-Enfants Malades, APHP, Imagine Institute, Filière G2M, MetabERN, INEM, University Paris Descartes, Paris, France
| | - Christophe Legendre
- Unit of Adult Nephrology and Transplantation, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière G2M, MetabERN, University Paris Descartes, Paris, France
| | - Marina Charbit
- Reference Center of Pediatric Nephrology, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière ORKID, ERKnet, University Paris Descartes, Paris, France
| | - Anne Scemla
- Reference Center of Inherited Metabolic Diseases, Hôpital Universitaire Necker-Enfants Malades, APHP, Imagine Institute, Filière G2M, MetabERN, INEM, University Paris Descartes, Paris, France
- Unit of Adult Nephrology and Transplantation, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière G2M, MetabERN, University Paris Descartes, Paris, France
| | - Claire Francoz
- Unit of Adult Hepatology and Transplantation, Hôpital Beaujon, Paris, France
| | - Jean-François Benoist
- Metabolic Biochemistry, Hôpital Universitaire Robert-Debré, APHP, Filière G2M, MetabERN, University Paris Sud, Paris, France
| | - Manuel Schiff
- Reference Center of Inherited Metabolic Diseases, Hôpital Universitaire Robert-Debré, APHP, Filière G2M, MetabERN, Paris, France
| | - Fanny Mochel
- Reference Center of Inherited Metabolic Diseases, Hôpital La Pitié Salpêtrière, APHP, Filière G2M, Paris, France
| | - Guy Touati
- Reference Center of Inherited Metabolic Diseases, Hôpital Universitaire Necker-Enfants Malades, APHP, Imagine Institute, Filière G2M, MetabERN, INEM, University Paris Descartes, Paris, France
- Reference Center of Inherited Metabolic Diseases, Hôpital Purpan, Filière G2M, Toulouse, France
| | - Pierre Broué
- Reference Center of Inherited Metabolic Diseases, Hôpital Purpan, Filière G2M, Toulouse, France
| | - Aline Cano
- Reference Center of Inherited Metabolic Diseases, Hôpital La Timone, Filière G2M, MetabERN, Marseille, France
| | - Marine Tardieu
- Reference Center of Inherited Metabolic Diseases, CHRU, Filière G2M, Tours, France
| | - Stefania Querciagrossa
- Department of Anesthesia, Hôpital Universitaire Necker-Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - David Grévent
- Department of Radiology, Hôpital Universitaire Necker-Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Olivia Boyer
- Reference Center of Pediatric Nephrology, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière ORKID, ERKnet, University Paris Descartes, Paris, France
| | - Laurent Dupic
- Intensive Care Unit, Hôpital Universitaire Necker-Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Mehdi Oualha
- Intensive Care Unit, Hôpital Universitaire Necker-Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Muriel Girard
- Pediatric Hepatology Unit, Reference Center for rare pediatric liver diseases, Department of Gastroenterology-Hepatology-Nutrition, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière Filfoie, ERN Transplantchild, Paris, France
| | - Yves Aigrain
- Unit of Pediatric Surgery and Transplantation, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière Filfoie, ERN Transplantchild, University Paris Descartes, Paris, France
| | - Dominique Debray
- Pediatric Hepatology Unit, Reference Center for rare pediatric liver diseases, Department of Gastroenterology-Hepatology-Nutrition, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière Filfoie, ERN Transplantchild, Paris, France
| | - Carmen Capito
- Unit of Pediatric Surgery and Transplantation, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière Filfoie, ERN Transplantchild, University Paris Descartes, Paris, France
| | - Chris Ottolenghi
- Reference Center of Inherited Metabolic Diseases, Hôpital Universitaire Necker-Enfants Malades, APHP, Imagine Institute, Filière G2M, MetabERN, INEM, University Paris Descartes, Paris, France
- Metabolic Biochemistry, Hôpital Universitaire Necker-Enfants Malades, APHP, Imagine Institute, Filière G2M, MetabERN, University Paris Descartes, Paris, France
| | - Rémi Salomon
- Reference Center of Pediatric Nephrology, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière ORKID, ERKnet, University Paris Descartes, Paris, France
| | - Christophe Chardot
- Unit of Pediatric Surgery and Transplantation, Hôpital Universitaire Necker-Enfants Malades, APHP, Filière Filfoie, ERN Transplantchild, University Paris Descartes, Paris, France
| | - Pascale de Lonlay
- Reference Center of Inherited Metabolic Diseases, Hôpital Universitaire Necker-Enfants Malades, APHP, Imagine Institute, Filière G2M, MetabERN, INEM, University Paris Descartes, Paris, France
| |
Collapse
|
3
|
Yang L, Gong NR, Zhang Q, Ma YB, Zhou H. Apparent Correlations Between AMPK Expression and Brain Inflammatory Response and Neurological Function Factors in Rats with Chronic Renal Failure. J Mol Neurosci 2019; 68:204-213. [PMID: 30919248 DOI: 10.1007/s12031-019-01299-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Accepted: 03/12/2019] [Indexed: 01/23/2023]
Abstract
To explore the correlations between AMP-activated protein kinase (AMPK) expression and brain inflammatory response and neurological function factors in rats with chronic renal failure. Chronic renal failure models in rats were established, and the healthy control group (normal group) was set. Chronic renal failure model rats were divided into model group (without any treatment), control group (intraperitoneal injection of normal saline), A-769662 group (intraperitoneal injection of AMPK specific activator), and compound C group (intraperitoneal injection of AMPK specific inhibitor). The results of HE staining showed renal tissue enlargement, and significant pathological changes. Compared with the normal group, AMPK level in peripheral blood and AMPK mRNA and protein expressions in brain tissue were significantly reduced, and AMPK pathway activation was significantly inhibited in other groups. Compared with the model group, rats in the A-769662 group had significantly decreased serum creatinine (Scr) and blood urea nitrogen (BUN) levels and γ-aminobutyric acid (γ-GABA) content, significantly increased brain-derived neurotrophic factor (BDNF) positive expressions and 5-hydroxytryptamine (5-HT) content, and decreased interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), and intercellular adhesion molecule 1 (ICAM-1) expressions (all P < 0.05), while it was just the opposite in compound C group (all P < 0.05). There is an apparent correlation between AMPK expression and brain inflammatory response in chronic renal failure rats. AMPK is expected to be an important pathway in the treatment of uremic encephalopathy.
Collapse
Affiliation(s)
- Li Yang
- Department of Nephrology, Nanfang Hospital, Southern Medical University, No. 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China
| | - Ni-Rong Gong
- Department of Nephrology, Nanfang Hospital, Southern Medical University, No. 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China
| | - Qin Zhang
- Department of Nephrology, Nanfang Hospital, Southern Medical University, No. 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China
| | - Ya-Bin Ma
- Department of Neurosurgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, No. 19 Nonglin Xia Road, Yuexiu District, Guangzhou, 510080, Guangdong Province, China
| | - Hui Zhou
- Department of Neurosurgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, No. 19 Nonglin Xia Road, Yuexiu District, Guangzhou, 510080, Guangdong Province, China.
| |
Collapse
|
4
|
Gabbi P, Ribeiro LR, Jessié Martins G, Cardoso AS, Haupental F, Rodrigues FS, Machado AK, Sperotto Brum J, Medeiros Frescura Duarte MM, Schetinger MRC, da Cruz IBM, Flávia Furian A, Oliveira MS, Dos Santos ARS, Royes LFF, Fighera MR, de Freitas ML. Methylmalonate Induces Inflammatory and Apoptotic Potential: A Link to Glial Activation and Neurological Dysfunction. J Neuropathol Exp Neurol 2017; 76:160-178. [PMID: 28395089 DOI: 10.1093/jnen/nlw121] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Methylmalonic acid (MMA) accumulates in tissues in methylmalonic acidemia, a heterogeneous group of inherited childhood diseases characterized by neurological dysfunction, oxidative stress and neuroinflammation; it is associated with degeneration of striatal neurons and cerebral cortical atrophy. It is presently unknown, however, whether transient exposure to MMA in the neonatal period is sufficient to trigger inflammatory and apoptotic processes that lead to brain structural damage. Here, newborn mice were given a single intracerebroventricular dose of MMA at 12 hours after birth. Maze testing of 21- and 40-day-old mice showed that MMA-injected animals exhibited deficit in the working memory test but not in the reference test. MMA-injected mice showed increased levels of the reactive oxygen species marker 2',7'-dichlorofluorescein diacetate, tumor necrosis factor, interleukin-1β, caspases 1, 3, and 8, and increased acetylcholinesterase activity in the cortex, hippocampus and striatum. This was associated with increased astrocyte and microglial immunoreactivity in all brain regions. These findings suggest that transient exposure to MMA may alter the redox state and cause neuroinflammatory/apoptotic processes and glial activation during critical periods of brain development. Similar processes may underlie brain dysfunction and cognitive impairment in patients with methylmalonic acidemia.
Collapse
Affiliation(s)
- Patricia Gabbi
- Programa de Pós-Graduação em Farmacologia, Centro, de, Departamento Fisiologia e Farmacologia, de Ciências da Saúde.,Laboratório de Bioquímica do Exercício, Centro, de, Departamento Métodos e Técnicas Desportivas, de Educação Física e Desportos, UFSM.,Centro, de Departamento Neuropsiquiatria; de Ciências da Saúde, UFSM
| | - Leandro Rodrigo Ribeiro
- Programa de Pós-Graduação em Farmacologia, Centro, de, Departamento Fisiologia e Farmacologia, de Ciências da Saúde.,Laboratório de Bioquímica do Exercício, Centro, de, Departamento Métodos e Técnicas Desportivas, de Educação Física e Desportos, UFSM
| | | | - Alexandra Seide Cardoso
- Programa de Pós-Graduação em Farmacologia, Centro, de, Departamento Fisiologia e Farmacologia, de Ciências da Saúde.,Laboratório de Bioquímica do Exercício, Centro, de, Departamento Métodos e Técnicas Desportivas, de Educação Física e Desportos, UFSM.,Centro, de Departamento Neuropsiquiatria; de Ciências da Saúde, UFSM
| | - Fernanda Haupental
- Programa de Pós-Graduação em Farmacologia, Centro, de, Departamento Fisiologia e Farmacologia, de Ciências da Saúde.,Laboratório de Bioquímica do Exercício, Centro, de, Departamento Métodos e Técnicas Desportivas, de Educação Física e Desportos, UFSM.,Centro, de Departamento Neuropsiquiatria; de Ciências da Saúde, UFSM
| | - Fernanda Silva Rodrigues
- Laboratório de Bioquímica do Exercício, Centro, de, Departamento Métodos e Técnicas Desportivas, de Educação Física e Desportos, UFSM.,Centro, de Departamento Neuropsiquiatria; de Ciências da Saúde, UFSM.,de Programa Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica
| | - Alencar Kolinski Machado
- Programa de Pós-Graduação em Farmacologia, Centro, de, Departamento Fisiologia e Farmacologia, de Ciências da Saúde
| | | | | | | | | | - Ana Flávia Furian
- Programa de Pós-Graduação em Farmacologia, Centro, de, Departamento Fisiologia e Farmacologia, de Ciências da Saúde
| | - Mauro Schneider Oliveira
- Programa de Pós-Graduação em Farmacologia, Centro, de, Departamento Fisiologia e Farmacologia, de Ciências da Saúde
| | - Adair Roberto Soares Dos Santos
- Programa de Pós-Graduação em Farmacologia, Centro, de, Departamento Fisiologia e Farmacologia, de Ciências da Saúde.,de Programa Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica.,Universidade Federal de Santa Catarina, Centro, de Programa Pós-graduação em Neurociências, de Ciências Biológicas
| | - Luiz Fernando Freire Royes
- Programa de Pós-Graduação em Farmacologia, Centro, de, Departamento Fisiologia e Farmacologia, de Ciências da Saúde.,Laboratório de Bioquímica do Exercício, Centro, de, Departamento Métodos e Técnicas Desportivas, de Educação Física e Desportos, UFSM.,de Programa Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica
| | - Michele Rechia Fighera
- Programa de Pós-Graduação em Farmacologia, Centro, de, Departamento Fisiologia e Farmacologia, de Ciências da Saúde.,Laboratório de Bioquímica do Exercício, Centro, de, Departamento Métodos e Técnicas Desportivas, de Educação Física e Desportos, UFSM.,Centro, de Departamento Neuropsiquiatria; de Ciências da Saúde, UFSM.,de Programa Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica
| | | |
Collapse
|